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Background. Cola acuminata seed, a commonly used stimulant in Nigeria, has been reportedly used for the management
of neurodegenerative diseases in folklore without scientific basis. This study sought to investigate the anticholinesterase and
antioxidant properties of aqueous extracts from C. acuminata seed in vitro.Methodology.The aqueous extract of C. acuminata seed
was prepared (w/v) and its effect on acetylcholinesterase (AChE) and butyrylcholinesterase activities, as well as some prooxidant
(FeSO
4
, sodium nitroprusside (SNP), and quinolinic acid (QA)) induced lipid peroxidation in rat brain in vitro, was investigated.
Results. The results revealed that C. acuminata seed extract inhibited AChE (IC
50
= 14.6 𝜇g/mL) and BChE (IC
50
= 96.2 𝜇g/mL)
activities in a dose-dependent manner. Furthermore, incubation of rat’s brain homogenates with some prooxidants caused a
significant increase 𝑃 < 0.05 in the brain malondialdehyde (MDA) content and inhibited MDA production dose-dependently and
also exhibited further antioxidant properties as typified by their high radicals scavenging and Fe2+ chelating abilities. Conclusion.
Inhibition of AChE and BChE activities has been the primary treatment method for mild Alzheimer’s disease (AD). Therefore,
one possible mechanism through which the seed exerts its neuroprotective properties is by inhibiting cholinesterase activities as
well as preventing oxidative-stress-induced neurodegeneration. However, this is a preliminary study with possible physiological
implications.
1. Introduction
Alzheimer’s disease (AD), first described by the German
neurologist Alois Alzheimer, is a neurodegenerative disease
affecting the brain, which is an irreversible, progressive brain
disease that slowly destroys memory and thinking skills
and eventually even the ability to carry out the simplest
tasks [1]. In recent years, studies have implicated oxidative
stress to play a crucial role in neurodegenerative diseases
such as Alzheimer’s disease via lipid peroxidation of cell
membrane of the neurons [2]. Of particular importance, the
brain is an organ extremely susceptible to free radical damage
because of its high consumption of oxygen and its relatively
low concentration of antioxidant enzymes and free radicals
scavengers. In most people, AD symptoms become visible
usually after age 60. AD sufferers generally have a reduced
amount of acetylcholine in their brain which accounts for the
cholinergic dysfunction which is associated with the disease.
Nowadays, the most prescribed drug class in pharmacother-
apy of AD is the cholinesterase inhibitors (ChEIs) that block
the breakdown of ACh [3]. Cholinesterases belong to a family
of proteins that is widely distributed throughout the body in
both neuronal and nonneuronal tissues and is classified as
either acetylcholinesterase (AChE) or butyrylcholinesterase
(BuChE) based on their substrate and inhibitor specificity [4].
Relevantly, production of free radicals andoxidative stress
metal accumulation such as iron, copper, and zinc in the beta-
amyloid plaques formed in the brains of ADpatients has been
claimed strongly to be associated with cognitive impairment
in negative manner [5]. Therefore, it is more substantial for
a drug candidate for treatment of AD to possess antioxidant
activity besides cholinesterase inhibition.
Although the etiology of Alzheimer’s disease (AD) is
not fully understood, nevertheless, inhibition of acetylcho-
linesterase (AChE) and butyrylcholinesterase (BChE) activ-
ity has been accepted as an effective treatment/management
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Figure 1: HPLC chromatograms of polyphenols and alkaloids in
Cola acuminata seeds. Separation of polyphenols was performed on
a LiChroCART 250-4 octadecylsilyl (ODS) C18, 5𝜇m particle (RP-
18 (5𝜇m)) column (Merck) at 26∘C. The guard column consisted
of a LiChroCART 4-4 LiChrospher 100 RP-18 (5𝜇m) (Merck). The
binary mobile phase consisted of 2% acetic acid in water (A) and
acetonitrile-water-concentrated acetic acid mixture (4 : 9 : 1 v/v/v)
(B). Letters or numbers over the peak indicate unidentified polyphe-
nolic compounds. (Source: [9]).
strategy against mild AD [6, 7]. AChE inhibitors such as
tacrine, donepezil, and rivastigmine are commonly used
synthetic drugs for the treatment of Alzheimer’s disease;
however, these drugs are limited in use due to their adverse
side effects. More recently, studies have shown that BChE
is found in significantly higher quantities in AD plaques
than in the plaques of age related nondemented brains [8].
However, most of the drug AChE inhibitors discovered do
not alter BChE activity which is very critical tomanagingAD.
Hence, recent efforts have focused on plant phytochemicals
as natural sources of effective AChE and BChE inhibitors
with little or no side effects which could be used as dietary
intervention in the management of this disease.
Cola is a tropical African genus which belongs to the
Sterculiaceae family. The genus comprises about 140 species
and the most commonly consumed is Cola acuminata (Pal.
de Beauv) (Russel [10]).Cola acuminata is a bitter brown seed
found in the pod of evergreen trees that are native to Africa.
It has a strong cultural significance in West Africa, where,
without these seeds, traditional hospitality and cultural and
social ceremonies are considered incomplete. In Europe,
America, and Nigeria, the seeds are used in the production
of several pharmaceutical drugs, wines, and liquors [11–
13]. The plant was introduced to the Central and South
American countrieswhere it becamepopular during the Slave
Trade of the 17th century. This popularity resulted from its
reputation as a stimulant, increasing energy and strength, dis-
pelling drowsiness, and staving off hunger [14]. In traditional
medicine, it is used in themanagement/treatment ofmemory
loss and other neurodegenerative conditions. Niemenak et
al., 2008 [9], reported that caffeine and theobromine were
the major purine alkaloids in Cola acuminata seeds while
catechin and epicatechin were the predominant polyphenols.
The HPLC chromatogram of polyphenols and alkaloids in
Cola acuminata is presented in Figure 1 as reported by
Niemenak et al., 2008 [9]. However, based on the continuous
search for natural products that are cholinesterase inhibitors
and also due to the fact that Cola acuminata is used in folk
medicine for memory-improvement till date, it is therefore
expedient to assess its anticholinesterase activity as well as
effect on some prooxidant (FeSO
4
, sodiumnitroprusside, and
quinolinic acid) induced oxidative stress in rats brain in vitro.
2. Materials and Methods
2.1. Sample Collection. Fresh samples of kola nut (Cola
acuminata) seeds were purchased at the Erekesan market in
Akuremetropolis, Nigeria. Authentication of the samples was
carried out at the Department of Biology, Federal University
of Technology, Akure, Nigeria.
2.2. Chemicals and Reagents. All chemicals used were
sourced from Sigma Co. (St. Louis, MO). Except if stated oth-
erwise, all the chemicals and reagents used are of analytical
grade, while the water used was glass distilled.
2.3. Aqueous Extract Preparation. The kola nut seeds were
thoroughly washed in distilled water to remove any dirt,
chopped into small pieces by table knife, air-dried, andmilled
into fine powder. The aqueous extracts of the seed were
prepared by soaking 5 g of the grinded samples in 100mL of
distilledwater for 24 hrs at 37∘C.Themixturewas later filtered
through Whatman number 2 filter paper and centrifuged at
4000 rpm to obtain a clear supernatant whichwas then stored
in the refrigerator for subsequent analysis [15].
2.4. In Vitro Anticholinesterase Assays. Inhibition of AChE
was assessed by amodified colorimetricmethod of Perry et al.
(2001) [16]. The AChE activity was determined in a reaction
mixture containing 200𝜇L of a solution ofAChE (0.415U/mL
in 0.1Mphosphate buffer, pH 8.0), 100 𝜇L of a solution of 5,5󸀠-
dithio-bis(2-nitrobenzoic) acid (3.3mM in 0.1M phosphate-
buffered solution, pH 7.0) containing NaHCO
3
(6mM),
extract dilutions (0 to 100 𝜇L), and 500 𝜇L of phosphate
buffer, pH 8.0. After incubation for 20min at 25∘C, acetylth-
iocholine iodide (100 𝜇L of 0.05mM solution) was added as
the substrate, and AChE activity was determined with an
ultraviolet spectrophotometer from the absorbance changes
at 412 nm for 3.0min at 25∘C. 100 𝜇L of butyrylthiocholine
iodide was used as a substrate to assay butyrylcholinesterase
enzyme, while all the other reagents and conditions were
the same. The AChE and BChE inhibitory activities were
expressed as percentage inhibition.
2.5. Lipid Peroxidation and Thiobarbituric Acid Reactions.
The lipid peroxidation assay was carried out using the
modifiedmethod ofOhkawa et al. [17]. 100mLS1 fractionwas
mixed with a reaction mixture containing 30mL of 0.1M pH
7.4 Tris-HCl buffer, extract (0–100mL), and 30mL of 70mM
freshly prepared sodiumnitroprusside.The volumewasmade
up to 300mL by water before incubation at 37∘C for 1 h. The
colour reaction was developed by adding 300mL 8.1% SDS
(sodiumdodecyl sulphate) to the reactionmixture containing
S1; this was subsequently followed by the addition of 600mL
of acetic acid/HCl (pH 3.4) mixture and 600mL 0.8% TBA
(thiobarbituric acid).Thismixture was incubated at 100∘C for
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1 h. TBARS (thiobarbituric acid reactive species) produced
were measured at 532 nm and the absorbance was compared
with that of standard curve using MDA (malondialdehyde).
2.6. ABTS Radical Scavenging Ability. The ABTS radical
(ABTS∙) (2,2󸀠-azino-bis(3-ethylbenzthiazoline-6-sulphonic








in the dark for 16 h and adjusting the Abs734 nm to 0.700
with ethanol. 0.2mL of appropriate dilution of the extract
was added to 2.0mL ABTS∙ solution and the absorbance was
measured at 734 nm after 15 minutes. The trolox equivalent
antioxidant capacity was subsequently calculated [18].
2.7. Fenton Reaction. The extract (0–100 𝜇L) was added to a
reaction mixture containing 120𝜇L of 20mM deoxyribose,
400 𝜇L of 0.1M phosphate buffer, and 40 𝜇L of 500𝜇M
of FeSO
4
, and the volume was made up to 800 𝜇L with
distilled water. The reaction mixture was incubated at 37∘C
for 30 minutes and the reaction was then stopped by the
addition of 0.5mL of 2.8% trichloroacetic acid. This was
followed by addition of 0.4mL of 0.6% thiobarbituric acid
(TBA) solution. The tubes were subsequently incubated in
boilingwater for 20minutes.The absorbancewasmeasured at
532. The OH∙ scavenging ability was subsequently calculated
[19].
2.8. DPPH Free Radical Scavenging Ability. The free radical
scavenging ability of the extracts against DPPH (1,1-diphenyl-
2 picrylhydrazyl) free radical was evaluated as described by
Gyamfi et al. (1999) [20]. Briefly, appropriate dilution of the
extracts (0–500𝜇L)wasmixedwith 1mL, 0.4mMmethanolic
solution containing DPPH radicals; the mixture was left in
the dark for 30min and the absorbance was taken at 516 nm.
The DPPH free radical scavenging ability was subsequently
calculated.
2.9. Fe2+ Chelation Assay. The Fe2+ chelating ability of the
extract was determined using a modified method of Minotti
and Aust [21], with a slight modification by Puntel et al.
[22]. Freshly prepared 500𝜇M FeSO
4
(150 𝜇L) was added
to a reaction mixture containing 168 𝜇L 0.1M Tris-HCl (pH
7.4), 218 𝜇L saline, and the extracts (0–25 𝜇L). The reaction
mixture was incubated for 5min, before the addition of
13 𝜇L 0.25% 1,10-phenanthroline (w/v). The absorbance was
subsequentlymeasured at 510 nm.TheFe (II) chelating ability
was subsequently calculated.
2.10. Determination of Total Phenol Content. The total phenol
content was determined by mixing 0.2mL of the sample
extract with 2.5mL 10% Folin-Ciocalteu reagent (v/v) and
2.0mL of 7.5% sodium carbonate was subsequently added.
The reaction mixture was incubated at 45∘C for 40min, and
the absorbance was measured at 765 nm using a spectropho-
tometer. Gallic acid was used as standard while the total
phenol content was subsequently calculated as gallic acid
equivalent [23].
2.11. Determination of Total Flavonoid Content. The total
flavonoid contentwas determined bymixing 0.5mLof appro-
priately diluted sample with 0.5mL methanol, 50𝜇L 10%
A1C1
3
, 50 𝜇L 1Mpotassiumacetate, and 1.4mLdistilledwater
and allowed to incubate at room temperature for 30min.
The absorbance of the reaction mixture was subsequently
measured at 415 nm; quercetin is used as standard flavonoid.
The total flavonoid content was subsequently calculated as
quercetin equivalent. The nonflavonoid polyphenols were
taken as the difference between the total phenol and total
flavonoid content [24].
2.12. Data Analysis. The results of replicate experiments were
pooled and expressed as mean ± standard deviation (SD)
[25]. A one-way analysis of variance (ANOVA) was used to
analyze the mean and the post hoc treatment was performed
using Duncan multiple range test. Significance was accepted
at 𝑃 < 0.05. The EC
50
(extract concentration causing 50%
enzyme inhibition/antioxidant activity) was performed using
nonlinear regression analysis.
3. Results
The AChE inhibitory potential of kola nut seed extract was
investigated and the result is shown in Figure 2(a); the result
revealed that the extract inhibited AChE activity in a dose-
dependent manner (0–63.3𝜇g/mL), having an IC
50
(extract
concentration causing 50% inhibition) value = 14.6 𝜇g/mL
as presented in Table 1. Also, the ability of the extract to
inhibit BChE activity in vitro was also investigated, and the
result is presented in Figure 2(b). The result revealed that
the extract inhibited BChE in a dose-dependent manner (0–
200𝜇g/mL) having an IC
50
(extract concentration causing
50% inhibition) value = 96.2 𝜇g/mL as presented in Table 1.
Furthermore, incubation of the rat brain homogenate
with some prooxidants caused a significant increase in
the MDA production as presented in Figures 3(a)–3(c),
respectively. However, the introduction of the extract inhib-
ited MDA production in a dose-dependent manner (0.16–
0.63mg/mL). The ABTS radical (ABTS∙) scavenging abil-
ity presented as trolox equivalent antioxidant capacity is
presented in Table 2. The result revealed that the extract
scavenged ABTS∙ (2.65mmol⋅TEAC/100 g). Also, the extract
scavenged DPPH radical and OH radical and exhibited
Fe2+ chelating activity in a dose-dependent manner as
shown in Figures 4(a)–4(c). Furthermore, the total phenol
(2.78mg⋅GAE/g) and flavonoid (1.75mg⋅QUE/g) contents of
the nut seeds are presented in Table 2.
4. Discussion
Inhibition of acetylcholinesterase is considered as a promis-
ing approach for the treatment of Alzheimer’s disease (AD)
and for possible therapeutic applications in the treatment
of Parkinson’s disease, ageing, and myasthenia gravis [26,
27]. Meanwhile, BChE has been considered to be directly
associated with the side effects of the AChE inhibitors and
the existing drugs of Alzheimer’s disease [28]. More recent
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Figure 2: Anticholinesterase inhibitory activity, (a) acetylcholinesterase inhibitory activity and (b) butyrylcholinesterase inhibitory activity,
of aqueous extract of Cola acuminata. Values represent means ± standard deviation of triplicate readings. Different letters above each
concentration indicate significant differences (𝑃 < 0.05).
Table 1: IC50 values for the acetylcholinesterase and butyryl-
cholinesterase inhibitory activities; inhibition of FeSO4, SNP, and
quinolinic acid inducedMDAproduction in rats brain homogenates
in vitro; OH∙ and DPPH∙ scavenging ability as well as Fe2+ chelating
ability.
Parameters Values (units)
Acetylcholinesterase 14.6 ± 1.04 (𝜇g/mL)
Butyrylcholinesterase 96.2 ± 7.07 (𝜇g/mL)
FeSO4 induced 0.16 ± 0.12 (mg/mL)
SNP induced 0.76 ± 0.10 (mg/mL)
QA induced 0.51 ± 0.04 (mg/mL)
DPPH∙ 2.10 ± 0.08 (mg/mL)
OH∙ 0.97 ± 0.03 (mg/mL)
Fe chelation 1.09 ± 0.14 (mg/mL)
Values represent means ± standard deviation of triplicate readings (𝑛 = 3).
studies have shown that BChE is found in significantly
higher quantities in AD plaques than in the plaques of age
related nondemented brains. Other recent studies have also
reported that the unfavorable side effects profile of AChE
inhibitors is not associated with their poor selectivity towards
AChE [29]. Thus, new cholinesterase inhibitors, in addition
to their potential clinical importance if followed by proper
pharmacological investigations, would help in defining the
role of BChE in brain development, health, and ageing and
would in the meantime reveal the value of both BChE and
AChE inhibition as a novel strategy for the treatment of AD.
In our present study, aqueous extract of C. acuminata
inhibited both AChE and BChE as presented in Figures 2(a)
and 2(b). The inhibition of these cholinesterases could be
as a result of the important phytochemicals such as caffeine
and flavonoids which have already been characterized in
this extract according to a previous work by Niemenak et
al., 2008 [9], as shown in Figure 1. Studies have shown that
caffeine is a noncompetitive inhibitor of acetylcholinesterase
but not BChE according to da Silva et al., 2008 [30], as well as
Pohanka and Dobes, 2013 [31]. Phenolic acids such as caffeic
acid, chlorogenic acids, and catechin have been reported to
be a potent inhibitor of both AChE and BChE [32, 33].
AChE is an important regulatory enzyme that controls the
transmission of nerve impulses across cholinergic synapses
by hydrolysing the excitatory transmitter acetylcholine (ACh)
[34, 35]. BuChE, also called nonspecific cholinesterase or
pseudocholinesterase, is able to act on hydrophilic and
hydrophobic choline esters [36]. At this moment, the exact
physiological function of BuChE is not yet clear, but it is well
known that this enzyme hydrolyses a variety of xenobiotics
such as aspirin, succinylcholine, heroin, and cocaine [37].
Recently, it was suggested that BuChE was found colocalised
with senile plaques in the central nervous system and plays a
role in the progressive beta-amyloid aggregation and in senile
plaques maturation [38].
Normally, in the healthy brain AChE is predominant.
However, in AD brain BChE activity rises while AChE
activity remains unchanged or diminished [39]. Therefore,
inhibition of both AChE and BChE by our extract is an
indication that the nut could have additive and potential
therapeutic benefits. Moreover, our result is in accordance
with literature data that also demonstrated AChE and BChE
inhibition by crude extracts from plant [40, 41].
Neurodegeneration due to oxidative stress has been
implicated in the pathogenesis and progression of AD, with
selective loss of cholinergic neurons in the brain being the
most prominent. Studies have reported the AD brain to be
under intensive oxidative stress [42] and decrease in the
cholinergic neurons has been shown to promote amyloid pro-
tein deposition in the AD brain which in turn favour amyloid
protein-associated oxidative stress and neurotoxicity [43].
Hence, augmenting/improvement in the body’s antioxidant
status through dietary means could be a practical approach
through which oxidative-stress-induced neurodegeneration
is controlled. In this study, incubation of rat brain tissues
in the presence of 250𝜇M FeSO
4
caused a significant (𝑃 <
0.05) increase in the MDA content of the brain as presented
in Figure 3(a). This finding agreed with earlier report by
Butterfield and Lauderback (2002) [44] where significant
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Figure 3: Inhibition of some prooxidants, (a) Fe2+, (b) sodium nitroprusside, and (c) quinolinic acid, induced lipid peroxidation in rat whole
brain by aqueous extract of Cola acuminata. Values represent means ± standard deviation of triplicate readings.
Table 2: ABTS∙ scavenging ability, total phenol content, and total
flavonoid content of kola nut (Cola acuminata) seeds aqueous
extract.
Parameters Values (unit)
ABTS∙ 2.65 ± 0.03 (mmol⋅TEAC/100 g)
Total phenol 2.78 ± 0.07 (mg⋅GAE/g)
Total flavonoid 1.75 ± 0.50 (mg⋅QUE/g)
Values represent means ± standard deviation of triplicate readings (𝑛 = 3).
increase in MDA production in rat brain was observed in
the presence of Fe2+. The increased lipid peroxidation in the
presence of Fe2+ could be attributed to the fact that Fe2+
can catalyze one-electron transfer reactions that generate
reactive oxygen species, such as the reactive OH∙, which




through the Fenton reaction [45].
Elevated Fe2+ content in the brain had been linked to a
host of neurodegenerative diseases and high Fe contents
have been localized to degenerate regions of brains from
Alzheimer’s disease patients, a finding also demonstrated in
animal models of the disease [46]. However, the introduction
of the nut extracts inhibited MDA production in rat brain
in a dose-dependent manner. This finding is consistent with
our earlier report where plant extracts inhibited Fe2+induced
lipid peroxidation in rat brain in vitro [44].
In addition, incubation of rat brain tissues in the presence
of 7mM sodium nitroprusside (SNP) caused a significant
(𝑃 < 0.05) increase in the MDA production in the brain
as presented in Figure 3(b). However, the extracts of the
nut inhibited MDA production in rat brain in a dose-
dependent manner. NO has been reported to contribute to




) produced in Fenton reaction to form the powerful
peroxynitrite (ONOO−). The ONOO− can then induce lipid
peroxidation, oxidation of proteins and DNA which leads to
ATP-dependent PARP (poly ADP-ribose polymerase) over-
activation causing neuronal ATP depletion, mitochondrial
dysfunction as well as inflammation, and, ultimately, cell
death [47].
Furthermore, incubating rat brain tissue homogenates in
the presence of QA (a well-known excitotoxin that induces
oxidative stress and damage) caused a significant (𝑃 < 0.05)
increase in the MDA production in the brain as shown in
Figure 3(c). This finding is in agreement with Butterfield
and Lauderback (2002) [44] where QA caused a significant
increase in the MDA content of rat brain in vitro. However,
the nut extracts inhibited MDA production in rat brain in
a dose-dependent manner. Quinolinic acid (QA) had been
reported to activate neurons expressingNMDAreceptors and
glutamate type excitotoxicity [48]. The mechanism through
which QA induces lipid peroxidation has been linked to
free radical generation resulting from overstimulation of
NMDA receptors. Increases in QA concentration are known
to be associated with several neurodegenerative diseases
including Alzheimer’s disease [49]. Free radical scavengers
and antioxidant enzyme inducers can protect neuronal tissue
against the oxidotoxicity of QA under in vitro and in vivo
conditions [50, 51].
Free radicals have an important role in pathogenesis
of a wide range of diseases including AD. Antioxidants
can prevent biological and chemical substances from free
radical-induced oxidative damage and stress. Consequently,
multipotent antioxidants have gained a great attention from
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Figure 4: Some antioxidant parameters: (a) DPPH free radical scavenging, (b) OH radical scavenging, and (c) Fe2+ chelating abilities of
aqueous extract of Cola acuminata. Values represent means ± standard deviation of triplicate readings.
scientists for their potential in treatment of many diseases
[52]. Since dysregulation of metal ions such as Fe2+, Cu2+,
and Zn2+ and consequential induction of oxidative stress
have been reported to be associated with AD [46], the
extracts were also decided on to screen for their antioxidant
activity. Therefore, the free radical scavenging ability of the
nut extracts was studied using moderately stable nitrogen-
centred radical species: ABTS radical [18], DPPH free radical
[20], and OH radical from the decomposition of deoxyribose
[19]. Our results revealed that the nut extract scavenges
free radicals in a dose-dependent manner as presented in
Table 2 and Figures 4(a) and 4(b). This is an important
antioxidant mechanism demonstrated by the plant and could
play some part in the prevention of oxidative-stress-induced
neurodegeneration.
Furthermore, the nut seed extract chelates Fe2+ in a
dose-dependent manner. Fe chelating ability may also be
one of the possible mechanisms through which antioxidants
phytochemicals in nut extract prevent lipid peroxidation in
tissues, and it may be by forming a complex with Fe, thus
preventing the initiation of lipid peroxidation [15].
5. Conclusion
In conclusion, aqueous extract of kola seed (Cola acumi-
nata) is rich in phenolic compounds and exhibited both
anticholinesterase and antioxidant activity. This seed showed
potential as functional food/or nutraceuticals in the man-
agement of neurodegenerative diseases such as Alzheimer’s
disease as it exhibited inhibitory activity on key enzymes
(acetylcholinesterase and butyrylcholinesterase) linked to
this disease. Therefore, one possible mechanism through
which the nuts exert their neuroprotective properties is
by inhibiting cholinesterase activities as well as preventing
oxidative-stress-induced neurodegeneration.However, this is
a preliminary study with possible physiological implications.
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